Summary It is generally believed that there is a direct correlation between asthma control and a patient's health-related quality of life (HRQL). Objective and subjective measures of asthma control are used interchangeably. A retrospective analysis from 8994 patients from 27 randomized, controlled clinical trials with persistent asthma was conducted to determine the degree of association which exists between objective (lung function) and subjective (symptoms, quality of life) measures. Assessments were made via forced expiratory volume in 1-second (FEV 1 ), self-reported symptoms and the Asthma Quality of Life Questionnaire (AQLQ) overall scores. Baseline percent predicted FEV 1 was weakly correlated with baseline symptom-free days (SFD) and baseline overall AQLQ scores (r ¼ 0.11 and 0.09, respectively; P o0.001). Changes in percent predicted FEV 1 correlated weakly with changes in SFD but was more strongly correlated with changes in overall AQLQ scores (r ¼ 0.26 and 0.38, respectively; P o0.001). Additionally, SFD at both baseline and endpoint were moderately correlated with overall AQLQ scores at baseline and endpoint (r ¼ 0.36 and 0.44; P o0.001). This study suggests that the impact of asthma on a patients' HRQL is not fully accounted for by objective measures such as lung function. Thus, HRQL data complements rather than duplicates results from traditional, objective assessments of asthma control.
Introduction
Asthma is major public health concern in the US, accounting for an estimated 14.5 million lost workdays for adults, 1 14 million lost school days for children 1 and significant healthcare cost. 2 In addition to the public health impact of the disease, uncontrolled asthma negatively impacts individual patients and their families.
Traditionally, the asthma severity and the adequacy of the control have been assessed by objective measures such as lung function tests, rescue short acting beta 2 -agonist use, airway hyperresponsiveness to external stimuli, and number of hospitalizations due to asthma. It has been assumed that if these objective clinical measures improve, then the patient's symptoms and quality of life must improve as well. However, this may not necessarily be the case. Although objective clinical measures provide valuable information about the status of the disease, they may be unable to fully assess whether patients feel better and can function better (physically, socially, and emotionally) in everyday life. 3 For example, patients may begin to show signs of clinical improvement based on objective measures, however if the treatment is inconvenient, has unwanted effects or clinical improvement does not reach a critical threshold, the patient might not feel better and/or might remain unable to function better while performing daily activities. On the other hand, patients may feel better and begin to experience an improvement in daily functioning, which may not be captured by the traditional clinical objective measures such as forced expiratory volume in 1-second (FEV 1 ) and hyperresponsiveness. Asthma may affect health-related quality of life (HRQL) in ways that objective clinical measures cannot predict. Symptoms are very important to patients; they are the most common reason people seek healthcare. However they alone may not reflect asthma severity. Symptoms may reflect the level of disease control achieved by treatment and selfmanagement while directly affecting the HRQL of patients.
Although there are many questions about the relationship between objective and subjective measures of asthma control, clinicians often use these measures interchangeably. It is generally believed that there is a strong direct correlation between objective and subjective measures of asthma control. The true nature of these correlations in asthma is poorly understood, therefore, we decided to perform several analyses to evaluate the association between asthma symptoms, lung function and HRQL in patients with persistent asthma.
Methods
This was a retrospective analysis of 27 randomized, double-blind, double-dummy, parallel group studies which examined the effects of inhaled corticosteroids, long-acting beta agonists, combination inhaled corticosteroids and long-acting beta agonists in a single inhaler, leukotriene modifiers, and placebo. Studies were selected from an internal clinical trials database on the bases of containing HRQL, lung function and symptom assessments at baseline and week 12. In addition, all studies had to be published in peer-reviewed journals. The details of each of these studies have been previously reported [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and are summarized in Table 1 . In order to have consistency between all studies, endpoint was defined as the value that occurred at week 12 regardless of the length of the study. Data from 12 to 85 year old adult and adolescent subjects with a diagnosis of persistent asthma for the previous 3 months, using the American Thoracic Society (ATS) definition, 24 requiring use of betaagonists and with no recent hospitalizations for asthma were used to determine the correlation between lung function, symptoms, and HRQL. Outcome measures were assessed at baseline and change over a 12-week period.
Pulmonary function measure
Lung function was measured by periodic in-clinic spirometry, which met or exceeded the minimum performance recommendations of the American Thoracic Society. 25 No beta-agonist use was permitted in the prior 6 h. Percent of predicted values for FEV 1 were calculated using the reference values of Crapo standards for ages 18 and older 28 and Polgar predicted normal values for ages 12-17.
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Symptoms measure
Patients were asked to record their symptom scores (based on wheezing, chest tightness, and shortness of breath), nighttime awakenings due to asthma, and supplemental albuterol on their diary cards at baseline and throughout the study. A symptom-free day (SFD) was defined as a day without asthma symptoms as reported in the subject's diary card (score of 0). A rescue-free day (RFD) was defined as a day where the number of puffs of albuterol for the relief of asthma symptoms was reported as zero on the diary card.
Health-related quality of life measure
The Asthma Quality of Life Questionnaire (AQLQ), 28 an instrument designed to measure the functional impairments that are most troublesome to asthma patients was used, on treatment day 1 and following 12 weeks of treatment or at the study discontinuation visit, to measure the changes in HRQL. The AQLQ is a self-administered instrument that has been shown to be valid, reliable and responsive to change in HRQL. [29] [30] [31] The AQLQ contains 32-items in 4 domains that assess the effect of drug treatment on activity limitations, symptoms, emotional function, and exposure to environmental stimuli. Patients recall their experiences of the previous 2 weeks. For the activity limitation domain, each patient selects 5 activities, from a list of 26, which are expected to remain important to them throughout the study. The other 3 domains have standard responses rated on a 7-point scale, with lower scores indicating greater impairment in asthma-related quality of life.
Statistical analysis
Data from 27 clinical studies with HRQL, lung function, and symptom assessments were combined for these retrospective analyses. Demographic and baseline characteristics were summarized by study and overall. Since the distribution of each of the assessments appeared to be symmetric and not markedly skewed, Pearson correlation coefficients and Pearson partial correlation coefficients were calculated to assess the relationships among percent predicted FEV 1 , overall AQLQ score, and patient-reported diary measures (percent SFDs, percent RFDs, and albuterol use) at baseline and at endpoint via change from baseline.
The baseline values for each patient for percent predicted FEV 1 and overall AQLQ score were defined as the measurement obtained immediately prior to randomization and endpoint values were defined as the measurement obtained following 12 weeks of treatment or at the study discontinuation visit, if prior to 12 weeks. Baseline for each patient-reported diary measure was obtained by calculating the mean of the measurements recorded on the 7 days preceding randomization and endpoint was calculated as the mean of the last week of measurements obtained prior to 12 weeks or the study discontinuation visit. The final week had to have at least 3 measurements to be included in these analyses. Linear regression equations were 32 were performed to explore associations among the assessments. Varimax rotation was done to group assessments (as factors) that were most highly correlated such that the resulting groups of assessments were uncorrelated. These analyses were conducted on data from baseline, endpoint, and change from baseline measurements.
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Results
Demographics and baseline characteristics
A total of 8994 patients from 27 clinical trials were included in this retrospective analysis. Enrollment in the individual trials ranged from 234 to 533 patients. 1985 subjects were randomized to placebo (22.1%) and 7009 subjects were randomized to active treatment (77.9%). The mean age for the study population was 36.5 years (7 SD 14.3; range 12-85), with a slightly higher proportion of females (53.6%) and a large proportion of whites (85.4%). The mean percent predicted FEV 1 was 65.6% (7 SD 10.7; range 25-110). About half of the population (55.9%) had experienced asthma symptoms for greater than 15 years and the same proportion of patients had prior use of inhaled corticosteroids (55.9%). Background characteristics of the intentto-treat populations were comparable among treatment groups at baseline. Table 2 displays the overall patient demographics and baseline characteristics of the study sample. Table 3 displays the baseline values and the mean change from baseline for the outcomes of interest. During these studies, percent predicted FEV 1 at baseline was 67.1% (7 SD 12.0; range 18.1-146.2) with a mean improvement of 7.6% (7 SD 14.0; range -54.2 to 80.6) by endpoint. At baseline, the mean percent symptom-free days was 13.1% (7SD 26.4; range 0-100) with mean improvements of 18.4% (7SD 38.4; range À100.0 to 100.0) by endpoint. The mean baseline scores for overall AQLQ scores was 4.5 (7 SD 1.06; range 1.2-7.0). At endpoint, the mean improvement in overall AQLQ scores was 0.75 (7 SD 1.1; range -4.8 to 5.3). Tables 4 and 5 display the relationship between HRQL, symptoms, lung function, rescue-free days and albuterol use at baseline and at change from baseline.
Correlation analyses
Baseline correlations
Baseline percent predicted FEV 1 was weakly correlated with baseline SFD, RFD, and albuterol use (r ¼ 0.11, 0.17, À0.22, respectively; P o0.001) ( Table 4 ). In addition, baseline percent predicted FEV 1 was weakly correlated with baseline overall AQLQ scores (r ¼ 0.09; P o0.001). Symptom-free days (SFD) at baseline was strongly correlated with baseline RFD (r ¼ 0.55, P o0.001). SFD at baseline was moderately correlated with baseline albuterol use (r ¼ À0.37, P o0.001). Overall AQLQ scores at baseline were moderately correlated with SFD, RFD, and albuterol use at baseline (r ¼ 0.36, 0.33, À0.37, respectively; P o0.001).
Change from baseline correlations Improvements in overall AQLQ scores also correlated moderately with improvements in SFD, RFD, and albuterol use at endpoint (r ¼ 0.44, 0.43, À0.49, respectively; P o0.001) ( Table 5) . At endpoint, changes in percent predicted FEV 1 correlated moderately with changes in overall AQLQ scores (r ¼ 0.38; P o0.001). Improvements in percent predicted FEV 1 were correlated weakly with changes in SFD, RFD, and albuterol use at endpoint (r ¼ 0.26, 0.27, À0.31, respectively; P o0.001). A strong correlation was also observed between SFD at endpoint and RFD at endpoint (r ¼ 0.59; P o0.001). Improvements in percent SFD at endpoint were moderately correlated with albuterol use at endpoint (r ¼ À0.40; P o0.001).
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Additional analyses were performed with subpopulations of treated, non-treated (subjects who received placebo), ICS na. ıve, and ICS experienced patients ( Figs. 1 and 2 ). These additional analyses show that the regression analyses comparing HRQL with lung function and symptoms were consistent regardless of the type of treatment or ICS use history.
Partial correlations
There was a moderate partial relationship between both lung function and HRQL and symptoms and HRQL at endpoint (r ¼ 0.31 and 0.38, respectively; Po0.001) (Fig. 3) . However there was only a mild partial correlation between lung function and symptoms at endpoint (r ¼ 0.10; Po0.001). Additional analyses were performed with subpopulations of treated, non-treated (subjects who received placebo), ICS na. ıve, and ICS experienced patients. Table 6 shows how these findings were consistent regardless of the type of treatment and ICS history. Lung function was measured via percent-predicted FEV 1 ; HRQL was assessed via overall AQLQ score; and symptoms were assessed via percent symptom-free days (SFD). The non-treated group was composed of patients who received placebo while the treated group was composed of patients who received active drug in the study. The ICS-na. ıve group was composed of patients who were not taking ICS at study entry while the ICS dependent were patients who were taking ICS at study entry. Figure 2 Regression analysis comparing change health-related quality of life (Overall AQLQ) scores with symptoms (symptom-free days). Patients were grouped into 5 subgroups. The All group included all patients in the retrospective study. The non-treated group was composed of patients who received placebo while the treated group was composed of patients who received active drug in the study. The ICS-na. ıve group was composed of patients who were not taking ICS at study entry while the ICS dependent were patients who were taking ICS at study entry.
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Principal components analyses
Consistent with the results obtained in Juniper, 32 the assessments grouped into four factors for baseline data. The first factor was composed of quality of life measurements, i.e., the AQLQ overall score and each domain score. The second factor was comprised of airway caliber measurements, in particular, FEV 1 and % predicted FEV 1 and morning and evening PEF. Symptom assessments and rescue albuterol use were grouped into the third factor. The fourth factor consisted of nighttime awakenings measurements. This suggests that each group (factor) represents a distinct component of asthma. This composition of the factors was similar for endpoint and change from baseline data.
Discussion
Important objectives of asthma therapy are to control symptoms and minimize the impact of the disease on patient functioning. 33 From a population management perspective, both disease management (asthma control) and impacts on HRQL are important issues. Asthma control is dependent on multiple factors such as medical/drug treatment, patient adherence, and disease severity. Asthma control determines patient health outcomes such as healthcare resource use, functional status and HRQL. Asthma control serves to assess the need and evaluate the quality of disease management programs and assess the response to different treatment options.
Findings from this retrospective study showed that HRQL as measured via the AQLQ overall scores correlated moderately with asthma symptoms (symptom-free days and rescue-free days) and albuterol use. Lung function as measured by changes in percent predicted FEV 1 correlated weakly to moderately with changes in HRQL and albuterol use while only correlating weakly with symptoms (symptom-free days and rescue-free days). Our findings show that even the correlation from other subjective measures such as symptoms may at the most be moderate because HRQL is just one component of symptom outcome and symptoms are just one of multiple factors affecting patient HRQL. For instance, in patients experiencing minor or short term lapses in their asthma control, a patient's HRQL may appear unaffected. However, in cases where the symptoms are extremely problematic or a lost of asthma control is experienced over a long period of time, a patient's HRQL may be highly impacted. Several of the HRQL parameters, such as activity levels, may not be greatly affected by changes in pulmonary function and symptoms. This may be because patients are learning to live with their disease by avoiding or omitting from their lifestyle those things that impact their disease and have the potential to exacerbate their symptoms. These patients may be experiencing a small amount of symptoms, nonetheless, the effect of the disease on their HRQL may be significant due to the changes they have been forced to make to their lifestyle. This study suggests that the impact of asthma on a patients' HRQL is not fully accounted for by objective measures such as lung function and albuterol use. There are additional factors that affect a patient's HRQL.
The mild correlation between lung function and symptoms was not surprising. Studies that have looked at the correlation between measures of asthma control and asthma severity have found, at the most, mild correlations. In one study, Charlton et al. 34 lung function, as assessed via peak flow was found not to be a key management of asthma. The authors suggested that an asthma-management plan based on symptoms alone might prove adequate, or even superior, to traditional clinical measurements.
Published reports of correlations between lung function and HRQL vary from no effect to moderate correlations. A hypothesis for the lack of strong correlation between lung function (FEV 1 ) and HRQL has been that FEV 1 represents a single time point measurement, whereas HRQL represents an average over days or weeks. 35 This limitation may be possible to overcome with daily measure of lung function such as PEF. However, PEF does not demonstrate a strong correlation with HRQL. Van der Molen and colleagues 36 compared two of the most frequently used asthma-specific QOL questionnaires (AQLQ and LWAQ) and two generic HRQL instruments (SF-36 and PGWB) agonist clinical objective measures of severity (FEV 1 , PEF, and PC 20 ) in order to establish the ability of HRQL questionnaires to discriminate asthma severity. The study found that the correlation between HRQL parameters and objective clinical measures (FEV 1 , PEF, and PC 20 ) were low while the correlations between HRQL parameters and subjective clinical measures (symptom scores and beta 2 -agonist use) were higher. Subjective measures were found to be related with each other. Symptom scores and beta 2 -agonist use were moderately correlated (r ¼ 0.40; Po0.001). Other studies have only found weak correlations between symptoms and albuterol use. 37 The findings from this study provide additional supporting evidence that objective measures only weakly or at the most moderately correlate with how patients actually feel and are able to function on a daily basis. Therefore patient's HRQL cannot be assumed or extrapolated from results of clinical objective measurements alone. Subjective patient information may be complementary to results from traditional clinical assessments.
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This study suggests that the impact of asthma on a patients' HRQL is not fully accounted for by objective measures such as lung function or albuterol use. As such, HRQL data complements rather than duplicates results from traditional, objective assessments of asthma control. Since a major goal of asthma therapy is to prevent symptoms, improve functional status and patients' sense of well-being, providers should include routine assessments of HRQL to understand the patient's perspective and provide a comprehensive approach to asthma control.
